These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11256110)

  • 21. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pentoxifylline: is it useful in multiple sclerosis?].
    Prieto JM; Dapena D; Lema M; Ares B; Cacabelos P; Noya M
    Rev Neurol; 2001 Mar 16-31; 32(6):529-31. PubMed ID: 11353990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
    Bayas A; Gold R
    J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
    Ostberg A; Pittas F; Taylor B
    Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW
    Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study.
    Feuillet L; Pelletier J; Suchet L; Rico A; Ali Cherif A; Pouget J; Attarian S
    Mult Scler; 2007 Apr; 13(3):348-56. PubMed ID: 17439904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to beta interferon 1b among Saudi patients with multiple sclerosis.
    Kargwell H; Yaqub BA; Al-Deeb SM
    Saudi Med J; 2003 Jan; 24(1):44-8. PubMed ID: 12590273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C; Vukusic S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of interferon in multiple sclerosis.
    McFarlin DE
    Ann Neurol; 1985 Oct; 18(4):432-3. PubMed ID: 2416264
    [No Abstract]   [Full Text] [Related]  

  • 36. [Endogenous biological retranslation in current clinical and biological studies].
    Cheknev SB
    Vestn Ross Akad Med Nauk; 2003; (4):28-34. PubMed ID: 12741357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of experimental recombinant interferons on multiple sclerosis.
    Johnson KP; Panitch HS
    Trans Am Clin Climatol Assoc; 1989; 100():171-6. PubMed ID: 2479162
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferons in relapsing remitting multiple sclerosis: a systematic review.
    Filippini G; Munari L; Incorvaia B; Ebers GC; Polman C; D'Amico R; Rice GP
    Lancet; 2003 Feb; 361(9357):545-52. PubMed ID: 12598138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon therapy for multiple sclerosis.
    Johnson KP; Panitch HS
    Md Med J; 1992 Jul; 41(7):601-3. PubMed ID: 1379317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trials of interferons in multiple sclerosis. What have we learned?
    Panitch HS; Bever CT
    J Neuroimmunol; 1993 Jul; 46(1-2):155-64. PubMed ID: 7689585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.